


CXCR4 antagonist 4

Cat. No.:	HY-144285
CAS No.:	2761009-30-5
Molecular Formula:	C ₂₉ H ₄₁ F ₂ N ₅
Molecular Weight:	497.67
Target:	CXCR; HIV
Pathway:	GPCR/G Protein; Immunology/Inflammation; Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CXCR4 antagonist 4 is a potent, orally active CXCR4 antagonist (IC ₅₀ =24 nM) with diminished CYP 2D6 activity, improved PAMPA permeability, potent inhibition of human immunodeficiency virus entry (IC ₅₀ =7 nM) ^[1] .																																											
IC₅₀ & Target	CXCR4 24 nM (IC ₅₀)	HIV 7 nM (IC ₅₀)																																										
In Vitro	<p>CXCR4 antagonist 4 (Compound 30, 0.1-10 μM, 48 hours) displays the inhibition potencies against the X4 virus in TZM-bl cells (IC₅₀=7 nM)^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td colspan="7">TZM-bl cells</td> </tr> <tr> <td>Concentration:</td> <td colspan="7">0.1, 1, 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td colspan="7">48 hours</td> </tr> <tr> <td>Result:</td> <td colspan="7">Displayed inhibition potencies against the X4 virus (IC₅₀=7 nM)</td> </tr> </table>								Cell Line:	TZM-bl cells							Concentration:	0.1, 1, 10 μM							Incubation Time:	48 hours							Result:	Displayed inhibition potencies against the X4 virus (IC ₅₀ =7 nM)										
Cell Line:	TZM-bl cells																																											
Concentration:	0.1, 1, 10 μM																																											
Incubation Time:	48 hours																																											
Result:	Displayed inhibition potencies against the X4 virus (IC ₅₀ =7 nM)																																											
In Vivo	<p>CXCR4 antagonist 4 (3, 10, 30 mg/kg) demonstrates better oral Bioavailability in a dose dependent and reached 27% for the 30 mg/kg^[1]. Pharmacokinetic Parameters of CXCR4 antagonist 4 in mice^[1].</p> <table border="1"> <thead> <tr> <th>Route</th> <th>Dose(mg/kg)</th> <th>T_{1/2}(h)</th> <th>C_{max}(ng/mL)</th> <th>C_{12h}(ng/mL)</th> <th>AUC_{0-8h} (h*ng/mL)</th> <th>% F_{PO} (0-8 h)</th> <th>Cl (L/h/kg)</th> <th>V_d (L/kg)</th> </tr> </thead> <tbody> <tr> <td>iv</td> <td>3</td> <td>5.89</td> <td>116</td> <td></td> <td>265</td> <td></td> <td>11.3</td> <td>96.3</td> </tr> <tr> <td>po</td> <td>3</td> <td></td> <td>12.8</td> <td>1.50</td> <td>34.3</td> <td>12.9</td> <td></td> <td></td> </tr> <tr> <td>po</td> <td>10</td> <td></td> <td>54.8</td> <td>14.3</td> <td>190</td> <td>215</td> <td></td> <td></td> </tr> </tbody> </table>								Route	Dose(mg/kg)	T _{1/2} (h)	C _{max} (ng/mL)	C _{12h} (ng/mL)	AUC _{0-8h} (h*ng/mL)	% F _{PO} (0-8 h)	Cl (L/h/kg)	V _d (L/kg)	iv	3	5.89	116		265		11.3	96.3	po	3		12.8	1.50	34.3	12.9			po	10		54.8	14.3	190	215		
Route	Dose(mg/kg)	T _{1/2} (h)	C _{max} (ng/mL)	C _{12h} (ng/mL)	AUC _{0-8h} (h*ng/mL)	% F _{PO} (0-8 h)	Cl (L/h/kg)	V _d (L/kg)																																				
iv	3	5.89	116		265		11.3	96.3																																				
po	3		12.8	1.50	34.3	12.9																																						
po	10		54.8	14.3	190	215																																						

po	30	169	34.8	717	27.1
----	----	-----	------	-----	------

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	mice ^[1]
Dosage:	3, 10, 30 mg/kg
Administration:	
Result:	Demonstrated better oral bioavailability in a dose dependent and reached 27% for the 30 mg/kg.

REFERENCES

[1]. Jecs E, et al. Synthesis and Evaluation of Novel Tetrahydronaphthyridine CXCR4 Antagonists with Improved Drug-like Profiles. J Med Chem. 2022, 65(5):4058-4084.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA